Drug intelligence / Profile preview

epigallocatechin-3-gallate + glatiramer acetate

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Subcutaneous
01

Overview

This is a combination of two agents:

  • Epigallocatechin-3-gallate (EGCG) is the main polyphenol in green tea, known for its antioxidant, anti-inflammatory, and neuroprotective properties. It acts by scavenging reactive oxygen species and modulating signaling pathways involved in inflammation and neuronal survival. EGCG has been studied as a neuroprotectant in various neurological diseases.
  • Glatiramer acetate is an immunomodulatory drug approved for the treatment of relapsing forms of multiple sclerosis (MS). It consists of synthetic polypeptides that mimic myelin basic protein and modulate immune responses by shifting T-cell populations from pro-inflammatory to anti-inflammatory phenotypes.

The combination has been investigated primarily for multiple sclerosis. Preclinical studies suggest synergistic effects on neuroprotection and immunomodulation—combining EGCG’s neuroregenerative actions with glatiramer acetate’s immune-modifying properties. However, clinical trials have not demonstrated significant additional benefit over standard therapy with glatiramer acetate alone in MS patients.

Other names
EGCG + glatiramer acetateepigallocatechin gallate + glatiramer acetate
02

Targets

Beyond the preview

Go deeper on epigallocatechin-3-gallate + glatiramer acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on epigallocatechin-3-gallate + glatiramer acetate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call